



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Reference: AMD03062026

Enquiries:

Stock queries:

Ms Babalwa Melitafa

E-mail:

Babalwa.Melitafa@health.gov.za

Contracting queries:

Ms Marione Schonfeldt

E-mail:

Marione.Schonfeldt@health.gov.za

Clinical queries:

Essential Drugs Programme

E-mail: SAEDP@health.gov.za

NOTICE: AMOXICILLIN, CLAVULANIC ACID; 600MG/5ML, 42.9MG/5ML; SUSPENSION

The Paediatric Hospital Level Standard Treatment Guidelines (STGs) and Essential Medicines List (EML)¹ recommend the preferential use of oral amoxicillin/clavulanic acid 14:1 ratio formulation dosed 12 hourly for all indications where it is recommended; over lower ratios (7:1 or 4:1).

The higher ratio formulations of amoxicillin/clavulanic acid such as the 14:1 ratio, are advantageous as they lead to less gastrointestinal adverse events (thus improving adherence), while still providing sufficient clavulanic acid for beta-lactamase inhibition.

An amoxicillin/clavulanic acid oral suspension with a 14:1 ratio (amoxicillin 600 mg/5ml plus clavulanic acid 42.9vmg/5ml) has been awarded on the latest Anti-infectives Tender (HP02-2025AI). See product details outlined in the table below.

NSN	Product	Contract	Supplier
222000960	Amoxicillin, Clavulanic Acid; 600mg/5ml, 42.9mg/5ml; Suspension; 100 ml	HP02-2025AI	Sandoz SA (Pty) Ltd
222000961	Amoxicillin, Clavulanic Acid; 600mg/5ml, 42.9mg/5ml; Suspension; 50 ml	HP02-2025AI	Sandoz SA (Pty) Ltd

Provinces are encouraged to order this item and make healthcare professionals aware of this formulation.

Circular dissemination:

Provinces and healthcare facilities are requested to distribute and communicate this information in consultation with the Pharmaceutical and Therapeutics Committees and all other relevant stakeholders.

Kind regards

MS KHADIJA JAMALOODIEN

CHIEF DIRECTOR: HEALTH PRODUCTS PROCUREMENT

DATE: 31/6/2026

¹ https://www.health.gov.za/wp-content/uploads/2026/03/Paediatric-STGs-and-EML-2025-2029-Review-Cycle_Updated-March-2026.pdf